Repligen Corporation Common Stock (RGEN)

FairStock Score: 36/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I am a patient value investor, and Repligen is a specialist in bioprocessing tools, consumables, systems, and analytics used in biologic-drug manufacturing. That niche can carry real switching costs, but the numbers must support the story. Revenue has grown: fiscal 2025, ended December 31, 2025, was $738.3 million versus $634.4 million in fiscal 2024, and the latest filed quarter, fiscal Q2 2026 ended June 30, 2026, produced $204.1 million versus $182.4 million in fiscal Q2 2025. However, profit quality has weakened sharply. Fiscal Q2 2026 net income was $5.0 million, or $0.09 per diluted share, down from $14.9 million and $0.26 in fiscal Q2 2025. Fiscal 2025 net income was $48.9 million after a fiscal 2024 loss of $25.5 million, which is why FairStock classifies it as a TURNAROUND. The balance sheet looks sound, with debt-to-equity of 0.33, an Altman Z-Score of 7.83, a Piotroski F-Score of 5/9, and trailing free cash flow of $110.2 million. Yet returns are weak: ROE of 1.99% and ROCE of 1.40%. At the October 13, 2026 close of $175.42, FairStock's P/E is 240.30, P/B is 4.69, FCF yield is 1.1%, EV/EBITDA is 58.18, and the Graham Number is $24.79. That is not a margin-of-safety price. I would need to see margins and returns recover before treating the current quote as fair.

In plain English: Repligen makes equipment and supplies used by companies that manufacture biologic medicines. Sales are growing slowly and the company is back to a small profit after a loss year, but earnings have fallen sharply in the latest filed quarter. At the recent closing price, the shares look expensive compared with the company's profit, cash flow, and accounting value.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer